The companies aim to identify and implement new and improved manufacturing routes for selected APIs by combining Codexis' directed evolution technology, which enables rapid enzyme discovery and optimization, with AMRI's process development and manufacturing capabilities, including its microbial strains.
"We are pleased to announce this partnership with Codexis, a company that shares our philosophy of prioritizing scientific problem solving, innovation and customer service," said AMRI's chairman, president and chief executive officer, Thomas E. D'Ambra, Ph.D. "Combining AMRI's expertise in chemistry, biocatalysis, quality assurance and manufacturing with Codexis' cutting-edge biocatalysis technology and services, creates a proprietary advantage to our customer's development projects. This is another example of the AMRI SMARTSOURCING™ strategy of creating partnerships to deliver better outcomes to our customers."
"Codexis selected AMRI for this collaboration because AMRI understands the opportunity to use biocatalysis for effective and comprehensive route assessment and manufacturing," said Dr. Peter Seufer-Wasserthal, senior vice president Pharmaceuticals, Codexis. "Both companies have established strong reputations in the pharmaceutical manufacturing industry. By working together, AMRI and Codexis should identify more opportunities, which will benefit both companies and their customers by developing innovative, cost-effective and practical chemical processes."